Literature DB >> 4123639

Baclofen and lithium in Huntington's chorea.

N E Andén, P Dalén, B Johansson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4123639     DOI： 10.1016/s0140-6736(73)93285-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  11 in total

Review 1.  Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.

Authors:  Chi-Tso Chiu; De-Maw Chuang
Journal:  Pharmacol Ther       Date:  2010-08-10       Impact factor: 12.310

Review 2.  Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders.

Authors:  Sweta Shah; Marc Marie Dooms; Sofia Amaral-Garcia; Mariana Igoillo-Esteve
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

Review 3.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

Review 4.  Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Authors:  Bronwen Martin; Erin Golden; Alex Keselman; Matthew Stone; Mark P Mattson; Josephine M Egan; Stuart Maudsley
Journal:  Histol Histopathol       Date:  2008-02       Impact factor: 2.303

5.  Effect of baclofen on tardive dyskinesia.

Authors:  J Gerlach; T Rye; P Kristjansen
Journal:  Psychopharmacology (Berl)       Date:  1978-03-01       Impact factor: 4.530

6.  Effects of baclofen on dopamine-dependent behaviors in mice.

Authors:  J J Balsara; M P Muley; A S Vaidya; A G Chandorkar
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

Review 7.  Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder.

Authors:  Chi-Tso Chiu; Zhifei Wang; Joshua G Hunsberger; De-Maw Chuang
Journal:  Pharmacol Rev       Date:  2013-01-08       Impact factor: 25.468

Review 8.  Targeting Tau to Treat Clinical Features of Huntington's Disease.

Authors:  Maria Masnata; Shireen Salem; Aurelie de Rus Jacquet; Mehwish Anwer; Francesca Cicchetti
Journal:  Front Neurol       Date:  2020-11-19       Impact factor: 4.003

Review 9.  Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward.

Authors:  Sara Melisa Arciniegas Ruiz; Hagit Eldar-Finkelman
Journal:  Front Mol Neurosci       Date:  2022-01-21       Impact factor: 5.639

Review 10.  Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned?

Authors:  Lisa Scheuing; Chi-Tso Chiu; Hsiao-Mei Liao; Gabriel R Linares; De-Maw Chuang
Journal:  Int J Biol Sci       Date:  2014-09-10       Impact factor: 6.580
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.